Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors' - Gritstone Bio ( NASDAQ:GRTS )

2 weeks ago

On Monday, Gritstone Bio Inc. GRTS revealed interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen-targeting immunotherapy, in frontline microsatellite-stable colorectal cancer ( MSS-CRC ) .

Ticker	Sentiment	Impact
GRTS	Neutral	42 %